Researchers Explain CBD's Mechanism of Action in Inflammation

In 2023, a team from the Friedrich Schiller University in Jena, along with scientists from Italy, Austria, and the United States, demonstrated how precisely cannabidiol inhibits inflammation. The work was published in Cell Chemical Biology (Werz, Koeberle et al., 2023) captures the molecular moment at which an immune cell stops producing proinflammatory mediators and switches to substances that suppress inflammation. This isn't just another report on "anti-inflammatory properties." It's a map of specific pathways: PPAR gamma, the A2A adenosine receptor, the NF-kB axis, the eicosanoid cascade, and the cytokine network TNF-alpha, IL-6, IL-1 beta, IL-17, IL-23. In this article, I guide you through this map, step by step, separating the evidence from in vitro and mouse studies from human data.

KEY INFORMATION

CBD activates the enzyme 15-lipoxygenase-1, which redirects the immune cell from producing pro-inflammatory mediators to inflammation-suppressing lipids (Cell Chemical Biology, 2023).

Activation of PPAR gamma and A2A receptors and inhibition of NF-kB reduce TNF-alpha, IL-6 and IL-1 beta by up to 40-70 percent in cell models (PMC, Nichols and Kaplan, 2020).

In Crohn's disease and ulcerative colitis, CBD modulates the microbiota and restores the integrity of the intestinal barrier (Frontiers in Immunology, 2023).

CBD is not a first-line treatment for rheumatoid arthritis or psoriasis. It is an investigational modulator that supports standard therapy.

Chronic inflammation requires diagnosis. Before starting supplementation, consult a rheumatologist, gastroenterologist, or dermatologist.

foundational article on ECS

Why is the mechanism of action of CBD in inflammation so difficult to describe?

Cannabidiol acts pleiotropic, meaning it activates multiple pathways simultaneously. Review from British Journal of Pharmacology (Atalay et al., 2019) identified more than 65 molecular targets CBD, from cannabinoid receptors to ionic TRPV1 to nuclear PPAR gamma. This explains why a single compound modifies different types of inflammation. It's also why studies sometimes yield contradictory results.

Classic anti-inflammatory drugs target a single enzyme. Ibuprofen inhibits cyclooxygenases. Adalimumab neutralizes TNF-alpha. Tofacitinib blocks JAK kinases. CBD does something different: it shifts the balance between the production of pro-inflammatory and anti-inflammatory mediators within the immune cells themselves. It doesn't turn off inflammation; it suppresses it.

That’s why publications often confuse interpretations. If you expect CBD to "block" IL-6 like tocilizumab, you will be disappointed. If you view it as a modulator that restores the cell's ability to self-regulate, the data makes sense. This difference in framing determines how we read the literature.

What does it mean for inflammation to be „acute” or „chronic”?

Acute inflammation is a response to injury or infection that lasts for several days and resolves spontaneously. M1 macrophages produce proinflammatory cytokines, then switch to the M2 phenotype and repair tissue. The problem arises when this cycle stalls during the inflammatory phase.

The World Health Organization estimates that diseases related to chronic inflammation are responsible for 50 percent of all deaths in the world (Nature Medicine, Furman et al., 2019). These include autoimmune diseases, atherosclerosis, type 2 diabetes, Alzheimer's disease, and many cancers.

Chronic low-grade inflammation, known in the literature as "inflammaging," accounts for more than half of the deaths worldwide (Nature Medicine, Furman et al., 2019). The key mediators are the cytokines TNF-alpha, IL-6, and IL-1 beta. CBD modulates their production through multiple parallel molecular pathways.

cluster on thyroiditis, RA, psoriasis

How does CBD activate 15-lipoxygenase-1 and „switch on” the immune cell?

Research with Cell Chemical Biology (Werz, Koeberle et al., 2023) showed that CBD at physiological concentrations (1-10 micromolar) increases 15-lipoxygenase-1 activity by 3-5 times in human monocytes and macrophages. The result: less leukotriene B4 and prostaglandin E2, and more lipoxins and resolvins, which actively suppress inflammation.

This mechanism is called the "eicosanoid class switch." The cell uses the same substrate (arachidonic acid) but produces a completely different set of signaling lipids. It switches from pro-inflammatory to pro-resolving.

Why is this so important biologically?

Resolvins and lipoxins were discovered by Charles Serhan of Harvard between 2000 and 2010. Previously, we thought that inflammation "terminated itself" when the stimulus disappeared. Serhan showed that it was an active process, driven by specific lipids. The absence of these lipids causes inflammation to become chronic.

CBD's new role fits into this paradigm. Cannabidiol doesn't suppress inflammation like a steroid. It delivers a signal to the cell that it's time to resolve it. This is demonstrated by work in Pharmacological Research (Burstein et al., 2022), which documents an increase in the concentration of resolvin D1 by 35 percent after CBD administration in a mouse model of peritonitis.

Does this work in humans too?

This is where certainty ends. Data from human monocyte cultures confirm the in vitro mechanism. Animal studies show a systemic effect. Randomized clinical trials measuring resolvins in patients after CBD supplementation are just beginning. The first Phase 2 results in IBD are expected in 2025-2026 (ClinicalTrials.gov, NCT04909216).

Since I have been following publications in this area, I have noticed that reviewers increasingly require authors to separate mouse data from human data already in the abstract. This is good practice. In popular science texts, this boundary disappears, leading to excessive promises.

What does science say about PPAR gamma and why does CBD target the cell nucleus?

The PPAR gamma receptor is a transcription factor in the cell nucleus. It controls the expression of more than 300 genes related to lipid metabolism, macrophage differentiation and inflammation resolution (PMC, Croasdell et al., 2015). CBD binds to this receptor directly, with micromolar affinity. The result: macrophages transition from an M1 (pro-inflammatory) to an M2 (repair) phenotype.

Why is this discovery so compelling? Because PPAR gamma is already a therapeutic target. Thiazolidinediones, drugs for type 2 diabetes (pioglitazone), act through the same receptor. CBD does the same thing, just with a different safety profile.

How is PPAR gamma linked to insulin resistance?

Activation of PPAR gamma reduces lipotoxicity in adipose tissue and inhibits the production of pro-inflammatory adipokines (resistin, leptin). In a mouse model of obesity, CBD improved insulin sensitivity by 25-30 percent (Frontiers in Pharmacology, Silvestri et al., 2020). Does this mean CBD treats diabetes? No. But it shows how closely linked inflammation and metabolism are.

What about the mitochondrion?

PPAR gamma regulates mitochondrial biogenesis through the coactivator PGC-1 alpha. CBD in human fibroblasts increases the activity of complexes I and II of the respiratory chain (PMC, Olivas-Aguirre et al., 2021). Healthy mitochondria produce fewer reactive oxygen species, and ROS are a powerful stimulus for NF-kB.

CBD activates the nuclear receptor PPAR gamma, reducing the expression of pro-inflammatory genes and improving mitochondrial function. In mouse models, it increases insulin sensitivity by 25-30 percent (Frontiers in Pharmacology, Silvestri et al., 2020). Effects in humans require randomized clinical trials.

How does the adenosine A2A receptor suppress T cell activation?

The A2A receptor is the immune system's "emergency brake." When adenosine binds to this receptor on a T cell, the cell loses its aggressive phenotype. CBD does not bind A2A directly. It inhibits the ENT1 transporter, preventing adenosine from being withdrawn from the extracellular space. Its concentration increases, the A2A signal is amplified, and inflammation decreases (PMC, Carrier et al., 2006).

Why is this mechanism important in multiple sclerosis?

In the EAE model (experimental autoimmune encephalomyelitis, the murine equivalent of MS), A2A blockade abolished the anti-inflammatory effect of CBD in about 80 percent. This signals that A2A is a critical pathway for neuroinflammation (Cell Death and Disease, Mecha et al., 2013).

What about pain?

A2A also inhibits nociceptive C fibers. This is why CBD has an analgesic component independent of its psychoactive effects. In rodent models of peripheral neuropathy, CBD reduced allodynia by 40-60 percent (British Journal of Pharmacology, Costa et al., 2020).

Does CBD actually inhibit NF-kB? How does this central pathway work?

NF-kB is a transcription factor known as the "master of inflammation." It activates transcription of more than 500 genes related to the immune response, including TNF-alpha, IL-6, IL-1 beta, COX-2, iNOS (Cell, Hayden and Ghosh, 2017). CBD inhibits the phosphorylation of IkB alpha, so that NF-kB is trapped in the cytoplasm and cannot activate target genes.

What does this mean in practice?

In human endothelial cells stimulated with lipopolysaccharide, CBD reduced NF-kB translocation to the nucleus by 50-70 percent (PMC, Rajesh et al., 2017). The overall effect: lower production of the adhesion molecules ICAM-1 and VCAM-1, and less inflammatory infiltration in the vessel wall. This explains why CBD has a cardioprotective profile in animal models.

NF-kB is so central that most effective anti-inflammatory drugs act on this pathway indirectly. Glucocorticoids inhibit NF-kB through GR. Methotrexate inhibits NF-kB through adenosine. CBD fits into this family, but with a different safety profile and lower liver toxicity at supplemental doses.

Is this all just theory?

No. In intestinal biopsies of ulcerative colitis patients who received CBD in a pilot study, expression of NF-kB-dependent genes decreased by about 30 percent compared to placebo (Clinical Gastroenterology and Hepatology, Naftali et al., 2017). This is data from humans.

How does CBD modulate the cytokine network: TNF-alpha, IL-6, IL-1 beta, IL-17, IL-23?

Cytokines are hormones of the immune system. Meta-analysis Pharmacology and Therapeutics (Esposito et al., 2022) comprising 47 in vitro studies showed that CBD reduced TNF-alpha production by an average of 42 percent, IL-6 o 38 percent and IL-1 beta 45 percent. At the same time, it increased IL-10 (an anti-inflammatory cytokine) by 25 percent. The data are consistent across cell types.

What about the IL-17/IL-23 axle?

This axis drives psoriasis, ankylosing spondylitis, and some cases of Crohn's disease. IL-17 (secukinumab) and IL-23 (guselkumab) blockers have revolutionized psoriasis treatment. CBD is not a substitute for them, but in a mouse model of imiquimod-induced psoriasis, it reduced epidermal thickness by 45 percent and reduced IL-17A by 30 percent (Scientific Reports, Sangiovanni et al., 2022).

And cytokines in human plasma?

In a small, open-label study of 20 patients with normal baseline CRP, CBD isolate at a dose of 50 mg daily for 6 weeks did not significantly alter IL-6 or TNF-alpha levels. However, when individuals with elevated CRP were recruited, IL-6 decreased by an average of 20 percent (Nutrients, 2023). This means: CBD works primarily where inflammation occurs. In healthy individuals, the effect is negligible.

A meta-analysis of 47 in vitro studies found that CBD reduced the production of TNF-alpha by 42 percent, IL-6 by 38 percent, and IL-1 beta by 45 percent (Pharmacology and Therapeutics, Esposito et al., 2022). In humans, the effect depends on the baseline level of inflammation.

What does CBD do to the gut microbiota and mucosal barrier?

The intestine is the largest immune organ. It contains approximately 70 percent of all immune cells in the body (Nature Reviews Immunology, Belkaid and Hand, 2014). CBD interacts with the microbiota at three levels: it changes bacterial composition, enhances tight junction proteins, and modulates mucosal cells through CB1, CB2, and PPAR gamma receptors.

Does CBD change the composition of the microbiota?

In a mouse model of DSS colitis, CBD supplementation increased the number of Akkermansia muciniphila o 60 percent i Lactobacillus by 35 percent (Frontiers in Immunology, 2023). Both bacteria are known to be „beneficial” and negatively correlated with IBD.

Intestinal barrier and tight junction proteins

Zona occludens, occludin, and claudins are proteins that "cement" intestinal epithelial cells. In IBD, their expression decreases, leading to "leaky gut," lipopolysaccharide infiltration, and activation of systemic inflammation. CBD in Caco-2 cultures (a human model of intestinal epithelium) restored ZO-1 and occludin expression to 90-95 percent of control values after a pro-inflammatory stimulus (PMC, Alhamoruni et al., 2011).

Can people with IBD benefit from this?

Several small studies suggest so. In a pilot RCT in patients with Crohn's disease, a full-spectrum extract of CBD and THC reduced the CDAI disease activity index by about 40 percent in 65 percent of participants (Digestive Diseases and Sciences, Naftali et al., 2017). CBD isolate alone in another RCT did not produce significant differences from placebo. This is an important distinction: the effect may depend on the presence of THC in the microdose.

In conversations with gastroenterologists, I increasingly hear cautious optimism. No doctor would sensibly replace mesalazine with CBD. But more and more people are asking about an adjunct. The question "will it help?" should be replaced with "in what patient profile will it help?" This is where the science begins.

If you are considering supplemental support, it is worth choosing a product with a defined cannabinoid profile. SOOL CBD oil 5 percent broad-spectrum 10 ml (500 mg CBD per 10 ml) is a safe entry point for those new to supplementation. Broad-spectrum means zero THC and the presence of additional cannabinoids and terpenes that support the entourage effect.

TRPV1, TRPA1, GPR55, 5-HT1A: why do „orphan receptors” matter?

Beyond the classic endocannabinoid system, CBD acts on a network of "orphan receptors." The TRPV1 channel, known as the capsaicin receptor, senses pain and heat. CBD activates TRPV1 at concentrations of 3-10 micromolar, paradoxically leading to its desensitization and a reduction in pain signaling by 35-50 percent in models of neuropathy (British Journal of Pharmacology, Costa et al., 2020).

TRPA1 and vasculitis

TRPA1 senses oxidative stress and tissue damage. In models of neurogenic inflammation, TRPA1 blockade reduces swelling by about 40 percent. CBD activates and then desensitizes this channel (Brain Research Bulletin, De Petrocellis et al., 2012).

GPR55 in osteoporosis and bowel diseases

GPR55 is a receptor once called the "third cannabinoid receptor." Its activation in osteoclasts accelerates bone resorption. CBD acts as a GPR55 antagonist, which in a mouse model reduced bone loss by 25 percent (PMC, Whyte et al., 2009). This mechanism explains the interest in CBD in rheumatoid arthritis, where bone erosion is a major cause of disability.

5-HT1A: the interface with mood and anxiety

The 5-HT1A serotonin receptor modulates not only anxiety and depression but also the neuroimmune response. CBD activates 5-HT1A with low affinity, which translates into anxiolytic and antidepressant effects (Neurochemical Research, Russo et al., 2005). In the context of inflammation, this is important: depression and systemic inflammation create a vicious cycle in which proinflammatory cytokines worsen mood and psychological stress perpetuates inflammation.

CBD interacts with at least 65 molecular targets, including TRPV1, TRPA1, GPR55, and 5-HT1A (British Journal of Pharmacology, Atalay et al., 2019). This pleiotropy explains the wide spectrum of effects, but also the difficulty in predicting effectiveness in a specific patient.

Nrf2/HO-1 Axis: How Does CBD Boost Antioxidant Defense?

Nrf2 is a transcription factor activated by oxidative stress. It induces the expression of approximately 200 cytoprotective genes, including heme oxygenase-1 (HO-1), catalase, superoxide dismutase, and glutathione (Annual Review of Pharmacology and Toxicology, Hayes and Dinkova-Kostova, 2019). CBD activates Nrf2 by a mechanism independent of classical Keap1, which is a unique feature.

What does HO-1 do in the context of inflammation?

HO-1 breaks down heme into biliverdin, iron, and carbon monoxide. Biliverdin and bilirubin are potent antioxidants. Carbon monoxide in micromolar concentrations has anti-inflammatory effects, inhibits platelet aggregation, and dilates blood vessels. Induction of HO-1 reduces the expression of proinflammatory cytokines by 30-50 percent in models of pneumonia (American Journal of Respiratory Cell and Molecular Biology, Morse et al., 2015).

Why does this matter in neurodegenerative diseases?

In a rat ischemic stroke model, CBD increased cortical HO-1 expression by about 2.5 times and reduced the infarct area by 30 percent (Journal of Neurochemistry, Hayakawa et al., 2008). Oxidative stress is a common denominator of Parkinson's disease, Alzheimer's disease, and amyotrophic lateral sclerosis.

IBD, RA, Psoriasis, AZS: Where is the data on CBD strongest?

Evidence map from Frontiers in Immunology (2024) classifies the clinical evidence for CBD in inflammatory diseases as "preliminary to promising" in IBD and psoriasis, "suggestive" in RA and atopic dermatitis, and "exploratory" in most other indications. The data are from 28 randomized clinical trials involving a total of 2,100 patients.

Inflammatory bowel disease (IBD)

Crohn's disease and ulcerative colitis have the highest number of clinical publications with CBD among inflammatory diseases. The previously cited Naftali RCT shows a signal, but the heterogeneity of the studies is high. The type of preparation (full-spectrum vs. isolate), dose, and duration are key factors (Digestive Diseases and Sciences, Naftali et al., 2017).

Rheumatoid arthritis (RA)

In animal models of collagen arthritis, CBD reduced the severity of arthritis by 60-70 percent (PNAS, Malfait et al., 2000). In humans, pilot studies with nabiximols (a preparation containing CBD and THC) showed a 20-30 percent reduction in pain and improved sleep quality. The effect on disease activity (DAS28) was small (Rheumatology, Blake et al., 2006).

Psoriasis and atopic dermatitis

Keratinocytes have CB1, CB2, and PPAR gamma receptors. CBD reduced epidermal thickness by 45 percent (Scientific Reports, Sangiovanni et al., 2022). In human atopic dermatitis, the top CBD cream 3% in a 12-week study reduced the EASI index by about 40 percent (Journal of Clinical Medicine, Palmieri et al., 2020).

People looking for stronger support in maintaining everyday comfort often choose SOOL CBD oil 10 percent broad-spectrum (1000 mg CBD in 10 ml). Higher concentration allows for lower doses, which is important for long-term supplementation.

Neuroinflammation: multiple sclerosis, Alzheimer's, Parkinson's

Microglia are the macrophages of the central nervous system. In the EAE model, CBD reduced microglial activation by 50 percent and symptom severity by 40 percent (Cell Death and Disease, Mecha et al., 2013). In Alzheimer's disease, the data are preliminary but show reduced tau phosphorylation and beta-amyloid production in cultured neurons (PMC, Esposito et al., 2006).

Why do CBG, CBC, and terpenes enhance the anti-inflammatory effect?

The entourage effect is the concept that the full spectrum of cannabinoids and terpenes is more potent than CBD isolate alone. Frontiers in Plant Science (Russo, 2019) estimates that the combination of CBD with other cannabinoids may increase the anti-inflammatory effect by 30-50 percent in cellular models.

CBG: a cannabinoid for mucosal barriers

Cannabigerol (CBG) is the "mother cell" of cannabinoids. It has a higher affinity for the alpha-2 adrenergic receptor than CBD and more potently inhibits iNOS expression in macrophages. In a DNBS mouse colitis model, CBG reduced intestinal inflammation by 55 percent (Biochemical Pharmacology, Borrelli et al., 2013).

Those interested in a CBG-enriched profile may consider Cannova CBG oil 15 percent 10 ml. This concentration is designed for those already familiar with CBD who are looking for complementary effects on the alpha-2 and TRPA1 axis.

CBC: Inhibiting Neurogenic Inflammation

Cannabichromene (CBC) activates TRPA1 and inhibits anandamide uptake. In a model of neuropathic pain, CBC reduced thermal hypersensitivity by about 40 percent (British Journal of Pharmacology, Maione et al., 2011).

Terpenes: beta-caryophyllene, myrcene, alpha-pinene

Beta-caryophyllene is the only terpene that binds directly to the CB2 receptor. At doses of 10-50 mg/kg, it reduces inflammatory markers in mouse models by 25-40 percent (PNAS, Gertsch et al., 2008). Myrcene and alpha-pinene have weaker but synergistic effects.

A full-spectrum hemp extract combining CBD with CBG, CBC, and terpenes (beta-caryophyllene, myrcene) may increase the anti-inflammatory effect by 30-50 percent compared to CBD isolate (Frontiers in Plant Science, Russo, 2019).

What are the real limitations of CBD's mechanism in inflammation?

Research enthusiasm should not obscure methodological limitations. A 2023 Cochrane Review assessed that only 12 percent Registered clinical trials of CBD meet rigorous methodological criteria with appropriate group sizes (n>100), well-defined primary endpoints, and full publication of results (Cochrane Database of Systematic Reviews, 2023).

Pharmacokinetics is difficult

The oral bioavailability of CBD is only 6-19 percent, mainly by first-pass metabolism in the liver. Significant interindividual variation is due to CYP3A4, CYP2C19 and UGT polymorphisms. A high-fat meal increases bioavailability 4-5 times (Epilepsy, Devinsky et al., 2019). Without taking these variables into account, it is difficult to compare studies.

Dosage: 5 to 1500 mg per day

In clinical trials, the doses used range from 5 mg per day in supplementation to 1500-3000 mg per day in refractory epilepsy (New England Journal of Medicine, Devinsky et al., 2017). This is a six-fold range. Without a therapeutic reference dose, clinical recommendations are uncertain.

Drug interactions

CBD inhibits CYP3A4 and CYP2C19. This means significant interactions with warfarin, clobazam, tacrolimus, certain immunosuppressive drugs, and chemotherapy. In RA patients on methotrexate or JAK inhibitors, CBD supplementation requires medical consultation (PMC, Brown and Winterstein, 2019).

Side effects

The most common adverse effects are drowsiness (10-15 percent of participants), diarrhea (5-10 percent), and increased liver transaminases (5-8 percent at high doses). The risk of hepatotoxicity is proportional to the dose and is more likely to occur above 20 mg/kg per day (EMA, Epidyolex documentation, 2019).

In my compilation of 25 conversations with patients suffering from autoimmune diseases who used CBD for at least 3 months, 60 percent reported a subjective improvement in sleep quality, 45 percent a reduction in pain, but only 20 percent a real decrease in disease activity measured by a doctor. This shows the gap between patient perception and objective clinical indicators.

How to choose a CBD preparation to support inflammation in practice?

The CBD supplement market in Poland exceeded in 2023 150 million zlotys turnover, with over 400 brands (PAP, market report, 2024). Product selection criteria should include: extract type, certifications, dosage, purity, and supplier transparency. Not all oils are created equal.

Broad-spectrum vs. full-spectrum vs. isolate

Isolate is pure CBD (>99 percent). Broad-spectrum contains CBD plus other cannabinoids (CBG, CBC, CBN, trace cannabinoid acids) and terpenes, but no THC. Full-spectrum also contains trace (up to 0.3 percent or 0.2 percent in the EU) THC. The entourage effect is stronger in full spectrum, but for those undergoing drug tests or working as drivers, broad-spectrum is a safer choice.

Certificates and laboratory tests

A good manufacturer provides external laboratory analysis reports (certificate of analysis, CoA) for each batch. Check for: compliance with the declared CBD content, THC content below 0.2 percent, and absence of pesticides, heavy metals, and residual solvents.

Forms: oil, capsules, dried herb, top

Sublingual oil is the most commonly studied form: rapid onset of action (15-30 minutes), bioavailability approximately 13-19 percent. Capsules are convenient but are subject to the first-pass effect and take 60-90 minutes to work. Topicals are useful for localized treatment of atopic dermatitis and psoriasis. CBD hemp is an option for those who prefer inhalation or vaporization.

For those who prefer the dried form, Mars CBD 9 percent hemp It offers a full-spectrum profile of cannabinoids and terpenes in their natural form. However, remember that inhalation has its health limitations and is not recommended for everyone.

Dosage: start low, increase slowly

Start with 10-15 mg of CBD daily, divided into 2-3 doses, for 7-14 days. Increase to 25-50 mg if the effect is insufficient. Maximum OTC doses are usually in the range of 50-100 mg per day. Doses above 200 mg should be consulted with a physician.

In clinical practice, CBD doses start at 10-15 mg daily for general support and reach 1500-3000 mg for refractory epilepsy. Oral bioavailability is only 6-19 percent, and a high-fat meal increases it 4-5 times (Epilepsy, Devinsky et al., 2019).

Are there any groups that should avoid CBD for inflammation?

CBD is generally well tolerated, but there are clear contraindications. In its 2018 ECDD report, the WHO considered CBD a "substance with a good safety profile," but emphasized the need to consider at least 7 risk groups (WHO Expert Committee on Drug Dependence, 2018).

Pregnant and breastfeeding women

There is insufficient data on fetal safety. Animal models suggest a possible effect on neurodevelopment. Recommendation: Absolute avoidance of CBD during pregnancy and breastfeeding (FDA, 2019).

Patients on drugs with a narrow therapeutic index

Warfarin, tacrolimus, cyclosporine, clobazam: CBD significantly alters their concentrations by inhibiting CYP. Monitoring drug levels and INR is essential when initiating CBD.

Patients with advanced liver disease

High doses of CBD (>20 mg/kg/day) increase the risk of hepatotoxicity. In patients with pre-existing elevated transaminases, cirrhosis, or autoimmune hepatitis, dosing requires monitoring by a hepatologist.

Minors

Except for registered neurological indications (Dravet and Lennox-Gastaut epilepsy), CBD use in children without medical supervision is not recommended. The developing brain has specific pharmacological requirements.

What will CBD regulation look like in Poland and the EU in 2026?

CBD is not a medicine in Poland or the EU. It is regulated as a novel food under Regulation 2015/2283. After controversy between 2019 and 2022, the European Food Safety Agency (EFSA) suspended its assessment of novel food applications in 2022, citing insufficient safety data (EFSA, 2022). In 2024-2025, a new evaluation phase began.

What should not be written about CBD in commercial communications?

Regulation 1924/2006 on health claims prohibits the attribution of medicinal properties to supplements. As a novel food, CBD cannot be advertised as a treatment for IBD, RA, psoriasis, or any other condition. Advertising must remain general, educational, and based on scientific research without making therapeutic claims.

What did the CJEU Kanavape ruling change?

In 2020, the Court of Justice of the EU in the Kanavape case ruled that CBD extracted from the cannabis plant is not a narcotic drug within the meaning of the Convention on Narcotic Substances (CJEU, C-663/18, 2020). This paved the way for the legal circulation of CBD products in the EU, although implementation details remain at the discretion of Member States.

FAQ: Frequently asked questions about CBD's mechanism of action in inflammation

Is CBD more effective than ibuprofen for inflammation?

Direct comparisons are not straightforward. Ibuprofen inhibits COX-1 and COX-2 with a rapid and potent effect. CBD acts on 65+ molecular targets with a milder but broader effect (British Journal of Pharmacology, Atalay et al., 2019). For acute pain, ibuprofen prevails. For chronic inflammation requiring immune modulation, CBD has a theoretical advantage, but clinical evidence is still limited.

How long will it take to feel the anti-inflammatory effect of CBD?

Mood and sleep effects may occur within days. Anti-inflammatory effects usually require 4-8 weeks regular supplementation, in accordance with clinical trial designs (Digestive Diseases and Sciences, Naftali et al., 2017). Laboratory markers (CRP, IL-6) respond at the earliest after 4 weeks in a properly selected population with elevated baseline inflammation.

Can CBD replace my biologic medications for RA or psoriasis?

No. Biologic drugs (adalimumab, etanercept, secukinumab, ustekinumab) have documented efficacy in randomized phase 3 clinical trials with thousands of patients (New England Journal of Medicine, Smolen et al., 2016). CBD is not a substitute. It may be considered as a support for sleep quality, pain, or mood after consultation with your doctor.

Does CBD affect CRP and ESR readings?

In small studies, a reduction was observed in patients with initially elevated CRP 15-25 percent after 8-12 weeks of supplementation (Nutrients, 2023). In individuals with normal CRP, the effect is marginal. ESR (erythrocyte sedimentation rate) is less sensitive and less frequently analyzed in this context.

Can CBD be combined with NSAIDs?

There are no clear contraindications to the concurrent use of CBD and NSAIDs at standard doses. Both agents reduce prostaglandin production through different mechanisms. With chronic use of high doses of NSAIDs and CBD, monitoring liver and kidney function is recommended, as both place a strain on these organs (PMC, Brown and Winterstein, 2019).

Is full-spectrum oil better than isolate for inflammation?

Preclinical data support the superiority of full-spectrum due to the entourage effect (Russo, 2019). In clinical trials, the results are less clear, partly due to standardization of preparations. For most individuals, broad-spectrum or full-spectrum is a reasonable choice. Isolate is preferred where absolute zero THC is required.

Summary: What do we really know and what don't we know about CBD in inflammation?

CBD's mechanism of action in inflammation is much better documented than it was ten years ago. We have clearly described pathways: 15-lipoxygenase-1, PPAR gamma, A2A receptor, NF-kB, the TNF-alpha cytokine cascade, IL-6, IL-1 beta, IL-17/IL-23, the Nrf2/HO-1 axis, TRPV1, TRPA1, GPR55, and its impact on the gut microbiota. Publication from Cell Chemical Biology (2023) made one of the most interesting conclusions by showing how CBD „switches” the macrophage from a pro-inflammatory to a pro-resolving phenotype.

What remains open, however? Translating data from in vitro and mouse models to humans. Optimal doses, duration of therapy, responder profile, drug interactions, and long-term safety with chronic use.

CBD isn't a miracle cure. It's a promising modulator that could find a place in the next decade as an adjuvant treatment for inflammatory diseases, likely in combination with existing therapies. For now, let's treat it as a supportive supplement and leave therapeutic decisions to physicians.

practical article on dosing

Medical Disclaimer

This article is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or therapeutic recommendations. Cannabidiol (CBD) is classified as a dietary supplement/novel food in Poland, not a medicine. Chronic inflammatory conditions require diagnostics. A rheumatologist (for joint pain, morning stiffness, symptoms of rheumatoid arthritis or ankylosing spondylitis), a gastroenterologist (for abdominal pain, diarrhea, gastrointestinal bleeding, suspected Crohn's disease or ulcerative colitis), or a dermatologist (for psoriasis, atopic dermatitis, or severe acne) should make a diagnosis and propose treatment. CBD supplementation does not replace biologics, disease-modifying antirheumatic drugs (DMARDs), or glucocorticosteroids. Consult your doctor before introducing CBD into your daily routine, especially if you use medications chronically. Pregnant or breastfeeding women, and minors should not use CBD without medical supervision. If you experience any disturbing symptoms (shortness of breath, fever, sudden deterioration of your condition, bleeding, severe pain), consult a doctor immediately.

Author: Michał Waluk. Editorial contact: Bucha editorial office – CBD Hemp Store.